Summary
For many years, small cell lung cancer treatments stayed mostly the same. Chemotherapy was the main option, and immunotherapy added in 2018 only helped a little. But now, new therapies are bringing real hope to patients and their families.
Dr. Triparna Sen, a professor at The Ohio State University, recently shared exciting news about progress in this disease. She explained that while lung cancer treatment as a whole has come a long way, small cell lung cancer fell behind for a long time. Today, that is finally changing.
Two new types of drugs are leading the way. The first group is called T-cell engagers. These drugs help the body’s own immune system find and attack cancer cells. Imdelltra (tarlatamab) and obrixtamig are two T-cell engagers showing strong results in clinical trials. Both target a protein called DLL3 found on small cell lung cancer cells.
The second group is called antibody-drug conjugates, or ADCs. These drugs act like guided missiles. They find specific proteins on cancer cells, such as B7-H3 and TROP2, and deliver treatment right to the tumor. This helps protect healthy cells.
Dr. Sen said these new small cell lung cancer treatments are showing survival gains in patients whose cancer has come back after earlier therapy. That is a group where progress has been very hard to reach. Researchers are also studying a drug called lurbinectedin combined with immunotherapy as a maintenance treatment.
The biggest change is that patients now have real options. After years of waiting, small cell lung cancer treatments are finally helping people live longer. Talk to your oncologist about clinical trials to see if these new therapies could be right for you.
